Tag Archives: Therapeutics

Intel, Home Depot, Palo Alto, Viking Therapeutics, Palantir, Medtronic, and More Movers  Barron’s Stocks making the biggest moves premarket: Intel, Palo Alto Networks, Best Buy and more  CNBC 5 Things to Know Before the Stock Market Opens  Investopedia Stocks to Watch Recap: Intel, Medtronic, Home Depot, Rocket Lab  The Wall Street Journal Stock Movers: Home Depot, Intel, Nvidia  Bloomberg Source link

Viking Therapeutics loses a third of its value after oral weight-loss drug trial  MarketWatch Viking Therapeutics shares fall 40% on disappointing obesity pill trial data  CNBC Viking Therapeutics (VKTX) Stock Fell More Than 30%. What Sent It Crashing.  Barron’s Viking’s oral pill reduces up to 12.2% weight but shares slump on higher patient exits  Reuters Viking Therapeutics Rises as Phase 3 Trials and Oral …

Investing.com — Viking Therapeutics (NASDAQ:VKTX) stock plunged as much as 37% Tuesday after revealing results from its Phase 2 VENTURE-Oral Dosing trial for its oral obesity treatment, while Eli Lilly (NYSE:LLY) shares gained 1.5% as analysts pointed to competitive advantages. The trial demonstrated that Viking’s oral tablet formulation of VK2735, a dual GLP-1 and GIP receptor agonist, met its primary …

Study Achieves Primary and Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight with Once-Daily VK2735 Dosing as Compared to Placebo Up to 12.2% (26.6 lbs) Mean Weight Loss Observed After 13 Weeks of VK2735 Treatment Compared with 1.3% (2.9 lbs) for Placebo Exploratory Assessment of Low Dose Maintenance Treatment Demonstrates Positive Proof of Concept VK2735 Shown to be Safe …

Viking Therapeutics (VKTX) stock dove on Tuesday following the release of data from a Phase 2 clinical trial of VK2735. This is the pharmaceutical company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is being developed in oral and subcutaneous formulations to treat various metabolic disorders, such as obesity. Elevate Your Investing Strategy: …

Tahoe cofounders (L-R): Kevin Shokat, Nima Alidoust, Johnny Yu and Hani Goodarzi Tahoe Therapeutics One of the holy grails of biology is digitally simulating a living cell. If researchers can use computers to more accurately understand how new medicines would react in the body, that could give them greater confidence when they’re tested on animals and humans. But while large …

Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments  Sarepta Therapeutics Sarepta to Report Q2 Earnings: What’s in Store for the Stock?  Nasdaq Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results  Yahoo Finance Sarepta Therapeutics Earnings Preview: Analysts Expect $1.01 EPS  AInvest Sarepta Therapeutics, Inc. SEC 10-Q Report  TradingView Source link

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. In a sharp reversal, the Food and Drug Administration on …

Investing.com — The U.S. Food and Drug Administration has recommended lifting the voluntary hold on Sarepta Therapeutics (NASDAQ:SRPT)’ gene therapy Elevidys for ambulatory patients with Duchenne Muscular Dystrophy (DMD). The FDA concluded that the death of an 8-year-old boy was unrelated to the gene therapy product itself, allowing ambulatory patients to once again receive the treatment. However, the voluntary hold …

Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS  Sarepta Therapeutics The crisis over Sarepta’s Duchenne therapy is a mess. But the lesson is clear  statnews.com FDA probes death of patient on Sarepta’s Elevidys, partner Roche says death unrelated to therapy  Reuters ‘We will crack gene therapy’: Elevidys fallout doesn’t dent Roche’s hopes for modality  Fierce Biotech FDA weighs new study requirements for Sarepta to confirm …